Plethora is focussed on the development and marketing of products for the treatment of urological disorders. The Company is focussed on: (i) seeking to increase the value of its development assets the most advanced of which is PSD502 for the treatment of premature ejaculation; and (ii) driving the development of its speciality sales and marketing business, The Urology Company
Plethora’s subsidiary, The Urology Company Limited, established in 2009, markets and distributes a range of branded and generic pharmaceutical products, pharmaceutical specials, medical devices and nutritional supplements for the treatment of urology, and obstetric conditions. Its products fall into two categories (i) Professional – where a physician, nurse or other healthcare professional makes a prescribing decision and (ii) Consumer – where the consumer/patient makes a buying decision.
24/04/12
Change of Registered Office29/03/12
Preliminary Results15/03/12
PSD502 Regulatory Submission Update23/01/12
Trading Statement20/01/12
Product Launch
15/03/12
Plethora Solutions this morning said it was delighted by the initial response to its first regulatory submissions for PSD502, a treatment for premature ejaculation. Investors also greeted the news, sending the stock higher.
15/03/12
Plethora Solutions this morning said it was delighted by the initial response to its first regulatory submissions for PSD502, a treatment for premature ejaculation.
04/05/12
Gemfields, Plethora Solutions, Silence Therapeutics and Digital Learning Marketplace to present at O30/04/12
Daniel Stewart raises Plethora Solutions target price, says its PE drug could go mass market29/03/12
Plethora Solutions gears up for landmark year UPDATE29/03/12
Plethora Solutions gears up for landmark year12/03/12
Plethora Solutions’ PE drug offers solution to wide-spread disorder - Hybridan
10/05/2012
15/03/2012
14/03/2012
14/02/2012
Plethora Solutions is a speciality pharmaceutical company dedicated to the development and marketing of products for the treatment and management of urological disorders.
The diagnosis and treatment of urological conditions represents an expanding market with many poorly met medical needs that offer significant commercial potential for new pharmaceutical products and medical devices.
Clinical Specialism
Sexual Dysfunction
Sexual dysfunction can arise from a variety of psychological and physical factors and encompasses the loss of sexual desire, pain during intercourse and the inability to obtain an erection (erectile dysfunction) or to enjoy or achieve orgasm. About 30 to 50% of women experience sexual dysfunction at some time during their life, while 20-30% of men will experience problems such as erectile dysfunction and premature ejaculation.
Speciality Areas
Uro-gynaecology
Uro-gynaecology is a sub-speciality of gynaecology which deals specifically with bladder and pelvic floor problems in women. While there are treatments for most of these conditions, many have limited efficacy and this field therefore constitutes an area of high poorly met medical need.
Dysmenorrhoea & Gynaecological Pain
Urinary Incontinence
Urinary incontinence (UI) is a condition where involuntary loss of urine is a social or hygienic problem. UI may be broadly divided into stress UI (SUI) and urge UI (UUI) although “mixed” incontinence is not uncommon.
Urinary incontinence affects both men and women. SUI is more commonly diagnosed in women and is associated with anatomical stresses caused by pregnancy and childbirth. Men may experience UUI as a result of prostate enlargement.
The Urology Company
The Urology Company is the marketing subsidiary of Plethora Solutions. The primary aim of the business is to work with partner companies internationally to provide healthcare professionals and patients in the UK with a comprehensive range of products for the treatment of urological disorders.
In particular the Company will focus on products for the treatment and management of urinary incontinence, obstetric and gynaecological conditions, urological pain, prostatic disease and male sexual dysfunction. The product portfolio comprises proprietary and generic pharmaceutical products and OTC products.
For further information on The Urology Company please click here
People
Plethora has brought together a dedicated team of people who have grown the company through their commitment and hard work. It has a Board of Directors and Executive Management Team with proven business, legal, financial and pharmaceutical industry backgrounds, offering the expertise for successful development and commercialisation of pharmaceutical products.
The Management Team
Mr Ronald Openshaw (Chief Executive Officer)
Ronald Openshaw has a significant track record in life sciences and healthcare sectors both in executive management and in an advisory role. He is the founder of the M&A and strategic consulting firm Lucia Capital LLP and previously he spent many years as an investment banker at Panmure Gordon & Co. Limited (latterly WestLB Panmure Limited) and then most recently Jefferies International Limited. He also served as CFO and acting CEO at Pharmagene plc until its merger with Asterand plc in 2006, where he remained as CFO to complete the integration in early 2007. Ronald qualified as a Chartered Accountant with KPMG.
Dr. Michael Wyllie (Chief Scientific Officer)
Mike Wyllie is a co-founder of Plethora. He has over 25 years of experience in senior management level positions within the pharmaceutical industry with American Home Products and Pfizer. He has considerable hands-on experience in all aspects of the drug discovery and development process and has been involved with new project inception, drug discovery and safety testing, early and late stage clinical development, regulatory filing and the successful commercialisation of products including Cardura® (doxazosin) and Viagra® (sildenafil). Dr. Wyllie sits on The Clinical Trial Design and Future Therapies in BPH Committees of the World Health Organisation International Consultations on Urological Disease and he is an assistant editor of the British Journal of Urology in the Sexual Medicine Section. He has over 100 publications and is named as the inventor of over 80 patents.
Nominated Advisor and Joint Broker
Daniel Stewart & Company Plc
36 Old Jewry
London
EC2R 8DD
Joint Broker
Hybridan LLP
29 Throgmorton Street
London
EC2N 2AT
Solicitors to the Company
Morrison & Foerster MNP
7th Floor
CityPoint
One Ropemaker Street
London EC2Y 9AW
Auditors
PricewaterHouseCoopers
Abacus House
Castle Park
Cambridge
CB3 0AN
Bankers
Lloyds TSB Bank plc
2nd Floor
PO Box 18436
39 Threadneedle Street
London EC2R 8PT
Registrars and Receiving Agent
Equiniti
PO Box 4630
Aspect House
Spencer Road
Lancing
West Sussex BN99 6QQ
Plethora Solutions Registered Office Address:
4th Floor
233 High Holborn
London WC1V 7DN
Email: mail@plethorasolutions.co.uk
Phone: +44 (0) 20 3077 5400
Fax: +44 (0) 20 3077 5440
| Significant shareholders | No shares | % |
|---|---|---|
| FOREST NOMINEES LIMITED | 9,348,180 | 14% |
| MERLIN GENERAL PARTNER III LIMITED | 8,059,180 | 12% |
| XCap Nominees Limited | 6,099,706 | 9% |
| J M Finn Nominees Limited | 4,575,000 | 7% |
| Newedge Group SA | 4,336,298 | 7% |
| Giltspur Nominees Limited | 2,876,041 | 4% |
| HSBC Global Custody Nomineed (UK) Limited | 2,689,394 | 4% |
| Sciele Pharma Cayman Limited | 1,772,505 | 3% |
| TD Waterhouse Nominees (Europe) Limited | 1,614,446 | 2% |
Copyright © Proactiveinvestors.co.uk, 2012. All Rights Reserved Design & Development: Tehnicom Computers
